• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal.

作者信息

Atasheva Svetlana, Shayakhmetov Dmitry M

机构信息

Lowance Center for Human Immunology, Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.

Lowance Center for Human Immunology, Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA; Emory Center for Transplantation and Immune-Mediated Disorders, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA; Discovery and Developmental Therapeutics Program, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

出版信息

Mol Ther. 2021 Mar 3;29(3):904-907. doi: 10.1016/j.ymthe.2021.02.001. Epub 2021 Feb 5.

DOI:10.1016/j.ymthe.2021.02.001
PMID:33577782
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7934625/
Abstract
摘要

相似文献

1
Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal.用于全身给药的溶瘤病毒：打造截然不同的模式。
Mol Ther. 2021 Mar 3;29(3):904-907. doi: 10.1016/j.ymthe.2021.02.001. Epub 2021 Feb 5.
2
Engineering Viruses to Fight Cancer.改造病毒以对抗癌症。
EBioMedicine. 2016 Jan 13;3:1. doi: 10.1016/j.ebiom.2016.01.014. eCollection 2016 Jan.
3
Introduction to Oncolytic Virotherapy.溶瘤病毒疗法简介。
Methods Mol Biol. 2020;2058:1-6. doi: 10.1007/978-1-4939-9794-7_1.
4
Gene therapy progress and prospects cancer: oncolytic viruses.基因治疗在癌症领域的进展与前景：溶瘤病毒
Gene Ther. 2008 Jun;15(12):877-84. doi: 10.1038/gt.2008.72. Epub 2008 Apr 17.
5
Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.用于人类溶瘤治疗的基因工程病毒的优化与临床前设计。
Expert Opin Biol Ther. 2012 Nov;12(11):1427-47. doi: 10.1517/14712598.2012.707183. Epub 2012 Jul 13.
6
Chapter four--Design of improved oncolytic adenoviruses.第四章——改良溶瘤腺病毒的设计。
Adv Cancer Res. 2012;115:93-114. doi: 10.1016/B978-0-12-398342-8.00004-5.
7
Oncolytic virus therapy using genetically engineered herpes simplex viruses.使用基因工程单纯疱疹病毒的溶瘤病毒疗法。
Front Biosci. 2008 Jan 1;13:2060-4. doi: 10.2741/2823.
8
Modification of oncolytic adenovirus and its application in cancer therapy.肿瘤溶瘤腺病毒的修饰及其在癌症治疗中的应用。
Discov Med. 2020 Nov-Dec;30(161):129-144.
9
The promise of microbial engineering for developing new strategies for tackling human disease.微生物工程在开发应对人类疾病新策略方面的前景。
Future Microbiol. 2012 Feb;7(2):167-9. doi: 10.2217/fmb.11.159.
10
Oncolytic Immunotherapy.溶瘤免疫疗法
Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5.

引用本文的文献

1
Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy.溶瘤病毒的全身递送策略：推进靶向高效肿瘤治疗
Int J Mol Sci. 2025 Jul 18;26(14):6900. doi: 10.3390/ijms26146900.
2
Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response.包裹于聚乙二醇化的DOTAP-叶酸脂质体中的腺病毒可免受预先存在的体液免疫反应的影响。
Pharmaceutics. 2025 Jun 11;17(6):769. doi: 10.3390/pharmaceutics17060769.
3
Advancing ORFV-Based Therapeutics to the Clinical Stage.将基于羊口疮病毒的疗法推进到临床阶段。
Rev Med Virol. 2025 May;35(3):e70038. doi: 10.1002/rmv.70038.
4
Strategies for engineering oncolytic viruses to enhance cancer immunotherapy.改造溶瘤病毒以增强癌症免疫疗法的策略。
Front Pharmacol. 2024 Sep 6;15:1450203. doi: 10.3389/fphar.2024.1450203. eCollection 2024.
5
Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer.用同源肿瘤细胞膜增强溶瘤病毒治疗胰腺癌的潜力。
IET Nanobiotechnol. 2024 Feb 13;2024:9970665. doi: 10.1049/2024/9970665. eCollection 2024.
6
Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.塞内卡山谷病毒及其生物标志物TEM8/ANTXR1在癌症治疗中的作用演变
Front Mol Biosci. 2022 Aug 26;9:930207. doi: 10.3389/fmolb.2022.930207. eCollection 2022.
7
Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.溶瘤病毒联合免疫检查点治疗结直肠癌是一种很有前途的治疗选择。
Front Immunol. 2022 Jul 15;13:961796. doi: 10.3389/fimmu.2022.961796. eCollection 2022.
8
Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles.聚酯纳米载体介导的基因传递的最新进展和挑战。
Int J Nanomedicine. 2021 Aug 31;16:5981-6002. doi: 10.2147/IJN.S321329. eCollection 2021.
9
Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.德国的病毒疗法——病毒工程、临床前开发和临床研究的最新活动。
Viruses. 2021 Jul 21;13(8):1420. doi: 10.3390/v13081420.

本文引用的文献

1
Systemic cancer therapy with engineered adenovirus that evades innate immunity.利用可逃避先天免疫的工程腺病毒进行全身性癌症治疗。
Sci Transl Med. 2020 Nov 25;12(571). doi: 10.1126/scitranslmed.abc6659.
2
Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy.间充质干细胞作为溶瘤腺病毒的载体细胞可增强溶瘤病毒治疗。
Sci Rep. 2020 Jan 16;10(1):425. doi: 10.1038/s41598-019-57240-x.
3
Checkpoint inhibitors go viral.检查点抑制剂迅速走红。
Nat Biotechnol. 2019 Jan 3;37(1):12-17. doi: 10.1038/nbt.4327.
4
Oncorine, the World First Oncolytic Virus Medicine and its Update in China.恩可欣，全球首款溶瘤病毒药物及其中国进展。
Curr Cancer Drug Targets. 2018;18(2):171-176. doi: 10.2174/1568009618666171129221503.
5
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.溶瘤病毒疗法可促进肿瘤内T细胞浸润并改善抗PD-1免疫疗法。
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
6
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.在OPTiM III期临床试验中接受talimogene laherparepvec（T-VEC）治疗的黑色素瘤患者的临床反应模式。
Ann Surg Oncol. 2016 Dec;23(13):4169-4177. doi: 10.1245/s10434-016-5286-0. Epub 2016 Jun 24.
7
First oncolytic virus approved for melanoma immunotherapy.首个获批用于黑色素瘤免疫治疗的溶瘤病毒。
Oncoimmunology. 2015 Dec 8;5(1):e1115641. doi: 10.1080/2162402X.2015.1115641. eCollection 2016.
8
Vesiculovirus neutralization by natural IgM and complement.天然 IgM 和补体对囊泡病毒的中和作用。
J Virol. 2014 Jun;88(11):6148-57. doi: 10.1128/JVI.00074-14. Epub 2014 Mar 19.
9
PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.囊泡性口炎病毒的聚乙二醇化延长了被动免疫小鼠血液循环中病毒的持续时间。
J Virol. 2013 Apr;87(7):3752-9. doi: 10.1128/JVI.02832-12. Epub 2013 Jan 16.
10
Complement and viral pathogenesis.补体与病毒发病机制。
Virology. 2011 Mar 15;411(2):362-73. doi: 10.1016/j.virol.2010.12.045. Epub 2011 Feb 2.